A deep-learning model may help predict lung cancer survival and outcomes

(American Association for Cancer Research) A deep-learning model developed using serial image scans of tumors from patients with non-small cell lung cancer (NSCLC) predicted treatment response and survival outcomes better than standard clinical parameters.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

This study quantifies the disturbing trend that, despite the expansion in the number of patients eligible for expensive and potentially toxic ICIs [immune checkpoint inhibitors], the ratio of those benefiting is decreasing,” wrote Dr. Daniel V.T. Catenacci, co-author of an editorial that accompanied the study in JAMA Network. “Observations in this article are sobering and remind us to keep expectations realistic.” Both Catenacci and Haslem agreed that the study should serve as a reminder to patients, physicians and policy makers to have more realistic discussions about the use of, and expectations of, the...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Abstract OBJECTIVE: Non-invasive distinction between squamous cell carcinoma and adenocarcinoma subtypes of non-small-cell lung cancer (NSCLC) may be beneficial to patients unfit for invasive diagnostic procedures or when tissue is insufficient for diagnosis. The purpose of our study was to compare the performance of random forest algorithms utilizing CT radiomics and/or semantic features in classifying NSCLC. METHODS: Two thoracic radiologists scored 11 semantic features on CT scans of 106 patients with NSCLC. A set of 115 radiomics features was extracted from the CT scans. Random forest models were develope...
Source: The British Journal of Radiology - Category: Radiology Authors: Tags: Br J Radiol Source Type: research
The objective of this study was to determine the feasibility of a novel thoracic magnetic resonance imaging (MRI) protocol incorporating diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) imaging for the assessment of the treated lung parenchyma after SBRT.
Source: Clinical Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
Publication date: August 2019Source: Biomedicine &Pharmacotherapy, Volume 116Author(s): Mao-Chi Weng, Ming-Hsin Li, Jing Gung Chung, Yu-Chang Liu, Jeng-Yuan Wu, Fei-Ting Hsu, Hsin-Ell WangAbstractNon-small cell lung cancer (NSCLC) is a malignant lung cancer type with poor prognosis. NF-κB, the oncogenic transcription factor, has been recognized as an important mediator in progression of NSCLC. Regorafenib, a multikinase inhibitor, was demonstrated to inhibit tumor progression through suppression of ERK/NF-κB signaling in hepatocellular carcinoma cells in vitro and in vivo. However, whether regorafenib inhib...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
In this study, a novel ultrasensitive FTO graphene nanosheets based electrode was used as a working probe to analyze the interaction between urokinase plasminogen activator (uPA) and monoclonal uPAR antibody (Ab). Graphene nanosheets (GNS) exhibited high conductivity, thereby increasing the sensitivity of the immunochemical assay. GNS were coupled with uPAR-Ab via carbodiimide activation chemistry with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)/N-hydroxysuccinimide (NHS) as a heterobifunctional crosslinker. The confirmation of immobilization events was done by biophysical methods such as UV–Vis spectroscopy,...
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research
In a study led by UCLA investigators, treatment with the immunotherapy drug pembrolizumab helped more than 15% of people with advanced non-small cell lung cancer live for at least five years — and 25% of patients whose tumor cells had a specific protein lived at least that long.When the study began in 2012, the average five-year survival rate was just 5.5%  for people with that type of cancer.The study, conducted by researchers at theUCLA Jonsson Comprehensive Cancer Center and more than 30 other centers, was the first to evaluate pembrolizumab as a treatment for lung cancer. The results were featured in aJune 1...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
CONCLUSIONS: Several potential prognostic biomarkers of PET/CT imaging have been extracted for predicting survival and selecting patients with NSCLC who are more likely to benefit from chemotherapy. The identification may accelerate the development of AI methods to improve treatment outcome for NSCLC. PMID: 31144578 [PubMed - in process]
Source: Molecular Imaging - Category: Radiology Tags: Mol Imaging Source Type: research
Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo. Biomed Pharmacother. 2019 Jun 01;116:109032 Authors: Weng MC, Li MH, Chung JG, Liu YC, Wu JY, Hsu FT, Wang HE Abstract Non-small cell lung cancer (NSCLC) is a malignant lung cancer type with poor prognosis. NF-κB, the oncogenic transcription factor, has been recognized as an important mediator in progression of NSCLC. Regorafenib, a multikinase inhibitor, was demonstrated to inhibit tumor progression through suppression of ERK/NF-&ka...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research
Authors: Shi XX, Pang HW, Ren PR, Sun XY, Wu JB, Lin S Abstract Purpose: To evaluate safety, feasibility, and efficacy of template-assisted 192Ir-based stereotactic ablative brachytherapy (SABT), combined with surgery for peripheral non-small cell lung cancer (NSCLC). Material and methods: Patients with pathologically confirmed operable peripheral NSCLC, who underwent template-assisted SABT (30 Gy delivered in one fraction) and were scheduled for tumor resection 4-6 weeks after SABT were included in this study. The perioperative adverse reactions of SABT were recorded to evaluate safety and feasibility of SABT ...
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
ConclusionsThe findings indicate that the PERCIST-based evaluation could identify progressive disease earlier. Early identification of nonresponders could lead to prevention of overtreatment and to an early switch to a  more effective therapy.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Learning | Lung Cancer | Non-Small Cell Lung Cancer | PET Scan | Universities & Medical Training